Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 50 references it cites were found in a registry or an index; 14 of the 21 sources its claims cite were checked for support.

Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK

Open access

Abstract

Background: Motor neuron disease is a progressive, fatal neurodegenerative disease for which there is no cure. Acceptance and Commitment Therapy (ACT) is a psychological therapy incorporating acceptance, mindfulness, and behaviour change techniques. We aimed to evaluate the effectiveness of ACT plus usual care, compared with usual care alone, for improving quality of life in people with motor neuron disease. Methods: We conducted a parallel, multicentre, two-arm randomised controlled trial in 16 UK motor neuron disease care centres or clinics. Eligible participants were aged 18 years or older with a diagnosis of definite or laboratory-supported probable, clinically probable, or possible familial or sporadic amyotrophic lateral sclerosis; progressive muscular atrophy; or primary lateral sclerosis; which met the World Federation of Neurology's El Escorial diagnostic criteria. Participants were randomly assigned (1:1) to receive up to eight sessions of ACT adapted for people with motor neuron disease plus usual care or usual care alone by a web-based system, stratified by site. Participants were followed up at 6 months and 9 months post-randomisation. Outcome assessors and trial statisticians were masked to treatment allocation. The primary outcome was quality of life using the McGill Quality of Life Questionnaire-Revised (MQOL-R) at 6 months post-randomisation. Primary analyses were multi-level modelling and modified intention to treat among participants with available data. This trial was pre-registered with the ISRCTN Registry (ISRCTN12655391). Findings: Between Sept 18, 2019, and Aug 31, 2022, 435 people with motor neuron disease were approached for the study, of whom 206 (47%) were assessed for eligibility, and 191 were recruited. 97 (51%) participants were randomly assigned to ACT plus usual care and 94 (49%) were assigned to usual care alone. 80 (42%) of 191 participants were female and 111 (58%) were male, and the mean age was 63·1 years (SD 11·0). 155 (81%) participants had primary outcome data at 6 months post-randomisation. After controlling for baseline scores, age, sex, and therapist clustering, ACT plus usual care was superior to usual care alone for quality of life at 6 months (adjusted mean difference on the MQOL-R of 0·66 [95% CI 0·22–1·10]; d=0·46 [0·16–0·77]; p=0·0031). Moderate effect sizes were clinically meaningful. 75 adverse events were reported, 38 of which were serious, but no adverse events were deemed to be associated with the intervention. Interpretation: ACT plus usual care is clinically effective for maintaining or improving quality of life in people with motor neuron disease. As further evidence emerges confirming these findings, health-care providers should consider how access to ACT, adapted for the specific needs of people with motor neuron disease, could be provided within motor neuron disease clinical services. Funding: National Institute for Health and Care Research Health Technology Assessment and Motor Neurone Disease Association. © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

Overview

CoChat Summary

## TL;DR

In this multicentre UK randomised controlled trial of 191 people with motor neuron disease, Acceptance and Commitment Therapy (ACT) plus usual care improved quality of life versus usual care alone at 6 months and 9 months. The intervention was also reported as acceptable, feasible to deliver (including remotely), and not associated with adverse events.

## Key findings

  • 191 participants were randomised: 97 to ACT plus usual care and 94 to usual care alone; primary outcome data were available for 155/191 (81%) at 6 months.
  • Quality of life on the MQOL-R was higher with ACT plus usual care at 6 months: adjusted mean difference 0·66 (95% CI 0·22 to 1·10), effect size d=0·46, p=0·0031; and at 9 months: 0·76 (0·30 to 1·22), d=0·53, p=0·0011.
  • Significant benefits also favored ACT plus usual care for MQOL-R psychological subscale, MQOL-R existential subscale, and modified-HADS depression at both 6 and 9 months, plus AAQ-II at 9 months and EQ-VAS at 6 months.
  • Acceptability/safety signals were strong: 70% (68/97) attended all eight sessions, 79% (69/87) rated therapy “satisfactory,” 86% (547/635) of sessions were delivered by video call, and 75 adverse events were reported with 38 serious, but no adverse events were deemed associated with ACT.

## Methods

  • Multicentre, parallel-group, two-arm randomised controlled trial in 16 UK motor neuron disease care centres/clinics; participants were randomised 1:1 to ACT plus usual care or usual care alone, with stratification by site.
  • Eligible participants were adults with ALS/motor neuron disease variants meeting El Escorial criteria; 191 people with motor neuron disease were recruited between Sept 18, 2019 and Aug 31, 2022. Caregivers could also participate if they were primary informal caregivers.
  • Primary outcome was MQOL-R total quality of life score at 6 months; analyses used multi-level mixed-effects models with random effect for therapist and fixed effects for age, sex, and baseline scores, on a modified intention-to-treat basis.

## Limitations

  • The paper states that subgroup and mediation findings should be interpreted with caution because of small numbers in depression subgroups, and because mediation assumed psychological flexibility changed before quality of life, which “cannot be verified since they were assessed at the same time.”
  • The trial’s primary outcome data were incomplete: 81% (155/191) were available at 6 months, and retention declined further by 9 months (70/97 and 68/94 had MQOL-R data).
  • Evident from the text: participants, caregivers, therapists, and treating clinicians could not be masked to allocation because of the nature of the intervention.

Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)00533-6

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

8 Valid · 4 Not valid · 1 Not checked · 90 Own results and interpretations

48 more claims

Create a free account to see all 103 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 38
  • Probably not a substantial claim. 28

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Cited by

See all 38

Metadata

Authors
Gould, R. L., McDermott, C. J., Thompson, B. J., Rawlinson, C. V., Bursnall, M., Bradburn, M., Kumar, P., Turton, E. J., White, D. A., Serfaty, M. A., Graham, C. D., McCracken, L. M., Goldstein, L. H., Al-Chalabi, A., Orrell, R. W., Williams, T., Noad, R., Baker, I., Faull, C., Lambert, T., Chhetri, S. K., Ealing, J., Hanratty, A., Radunovic, A., Gunawardana, N., Meadows, G., Gorrie, G. H., Young, T., Lawrence, V., Cooper, C., Shaw, P. J., Howard, R. J., Andreou, P., Androulaki-Korakaki, D., Blakeley, C., Bridges, G., Campbell, I., Davenport, B., Dee, A., Drewry, N., Flood, J., Fox, A., Girling, M., Glew, R., Hartley, N., Hocking, S., Howell, M., Keetharuth, A., Makin, S., Marsh, J., Mayberry, E., McDonald, A., McPartland, R., Meldrum, S., Mobley, A., Murphy, D., O'Brien, M. C., Oliver, M., Patel, D., Phipps, E., Read, J., Roberts, R., Rooney, N., Smith, C., Statham, J., Thompson, C., Varma, P., Walker, A. M., & Waterhouse, S.
Affiliations
  • University College London (GB)
  • NIHR Sheffield Biomedical Research Centre (GB)
  • University of Sheffield (GB)
  • Barts Health NHS Trust (GB)
  • University of Strathclyde (GB)
  • Uppsala University (SE)
  • King's College London (GB)
  • UCL Queen Square Institute of Neurology (GB)
  • Derriford Hospital (GB)
  • Swansea Bay University Health Board (GB)
  • University Hospitals of North Midlands NHS Trust (GB)
  • Lancashire Teaching Hospitals NHS Foundation Trust (GB)
  • Northern Care Alliance NHS Foundation Trust (GB)
  • South Tees Hospitals NHS Foundation Trust (GB)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • Northern Lincolnshire and Goole Hospitals NHS Foundation Trust (GB)
  • Queen Elizabeth University Hospital (GB)
Corresponding author
Gould, Rebecca L
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-06
Volume
403
Issue
10442
Pages
2381-2394
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4396764086
Cited by
38
References
50
Citations by year
2026: 14 · 2025: 18 · 2024: 6
FWCI
18.94
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
  • Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion, cc-by)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion, cc-by)
  • PEARL (University of Plymouth) (submittedVersion)
Funders
  • Motor Neurone Disease Association
  • National Institute for Health and Care Research School for Primary Care Research
Topics
  • Social Sciences › Psychology › Clinical Psychology › Mindfulness and Compassion Interventions
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
acceptance and commitment therapy, motor neuron disease, quality of life, amyotrophic lateral sclerosis, progressive muscular atrophy, primary lateral sclerosis, psychotherapy, mindfulness, behaviour change techniques, usual care comparison, patient-reported outcomes, neurodegenerative disease care, alcoholic beverages
MeSH terms
Aged, Female, United Kingdom, Humans, Male, Middle Aged, Quality of Life, Motor Neuron Disease, Treatment Outcome, Acceptance and Commitment Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00533-6
The paper
Gould, R. L., McDermott, C. J., Thompson, B. J., Rawlinson, C. V., Bursnall, M., Bradburn, M., Kumar, P., Turton, E. J., White, D. A., Serfaty, M. A., Graham, C. D., McCracken, L. M., Goldstein, L. H., Al-Chalabi, A., Orrell, R. W., Williams, T., Noad, R., Baker, I., Faull, C., . . . Waterhouse, S. (2024). Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK. The Lancet. https://doi.org/10.1016/s0140-6736(24)00533-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.